inspirator schreef op 5 april 2016 20:38:
Overname Galapagos door Gilead kan morgen bewaarheid worden:
The biotech giant has as much as $26 billion in cash on its books which can be used for a massive acquisition. Investors have been pressing for a deal that will immediately boost Gilead’s portfolio and relatively small pipeline. Last December, the drugmaker came out with a $725 million buyout of a stake in Belgian drugmaker, Galapagos NV, for its experimental final-stage JAK-1 inhibitor for treatment of inflammatory diseases. This time, it has come out with a barely $1.2 billion deal. While both deals can potentially add blockbuster medicines to Gilead’s portfolio, this is far from what shareholders expected from the giant. The company seems to be biding its time before a truly attractive takeover target comes along. Though biotech valuations exist at an all-time low at this point with the index down more than 20% since start of this year, Gilead’s search still continues – a dilemma for the market.
www.bidnessetc.com/66650-gilead-scien...